Google Play icon

New drugs a good BET for brain cancer

Share
Posted March 25, 2013

Glioblastoma – the most common and aggressive type of primary brain tumor – has complex genetic and signaling pathway defects. Therapies targeting a single defective protein or pathway have had limited efficacy.

A novel class of drugs that target BET proteins, which participate in “epigenetic” processes in the cell nucleus, has recently shown therapeutic potential against several blood cancers and a rare carcinoma.

Jialiang Wang, Ph.D., assistant professor of Neurological Surgery, and colleagues assessed the effects of the BET inhibitor JQ1 on genetically heterogeneous glioblastoma samples. They demonstrate that JQ1 causes programmed cell death (apoptosis) of cultured glioblastoma cells with different genetic backgrounds, and that reducing the expression of individual BET proteins in the cells mimics JQ1’s effects. They also showed that JQ1 represses the growth of glioblastoma tumors in a mouse model.

The findings, reported in Clinical Cancer Research, suggest that epigenetic mechanisms – such as those mediated by BET proteins – may be commonly required by glioblastoma and that BET inhibitors like JQ1 may have broad utility for treating these genetically diverse tumors.

Source: Vanderbilt University

Featured news from related categories:

Technology Org App
Google Play icon
85,582 science & technology articles

Most Popular Articles

  1. New treatment may reverse celiac disease (October 22, 2019)
  2. The World's Energy Storage Powerhouse (November 1, 2019)
  3. Universe is a Sphere and Not Flat After All According to a New Research (November 7, 2019)
  4. "Helical Engine" Proposed by NASA Engineer could Reach 99% the Speed of Light. But could it, really? (October 17, 2019)
  5. ‘Artificial leaf’ successfully produces clean gas (October 22, 2019)

Follow us

Facebook   Twitter   Pinterest   Tumblr   RSS   Newsletter via Email